FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein, expressed not only in prostate cancer but also in the endothelium of tumor-associated neovascular malignancies such as head and neck, breast, bladder, lung, gastric, colorectal, and gynecologic cancers [49].